Compare CINT & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CINT | FULC |
|---|---|---|
| Founded | 1995 | 2015 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 646.9M | 535.5M |
| IPO Year | 2021 | 2019 |
| Metric | CINT | FULC |
|---|---|---|
| Price | $4.71 | $7.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 8 |
| Target Price | $7.35 | ★ $16.38 |
| AVG Volume (30 Days) | 68.1K | ★ 912.5K |
| Earning Date | 05-12-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $16.69 | N/A |
| Revenue Next Year | $11.28 | N/A |
| P/E Ratio | $17.94 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.98 | $3.39 |
| 52 Week High | $6.71 | $15.74 |
| Indicator | CINT | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 42.68 | 50.77 |
| Support Level | $4.53 | $6.35 |
| Resistance Level | $5.02 | $8.20 |
| Average True Range (ATR) | 0.22 | 0.52 |
| MACD | -0.01 | 0.13 |
| Stochastic Oscillator | 33.33 | 73.29 |
CI&T Inc operates as a partner in tech-integrated business solutions, helping organizations address complex challenges by integrating business approach, technology, and artificial intelligence into a single, coherent operating model. It is mainly engaged in the development of customizable software through the implementation of software solutions, including machine learning, artificial intelligence, data analytics, cloud migration and mobility technologies. The company provides technology services to various industry verticals, including Financial Services, Consumer Goods, Technology and Communications, Retail and Industrial Goods, Life Sciences, among others. The majority of the revenue is derived from providing technology services. Geographically, maximum revenue is derived from Brazil.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.